promising results for blinatumomab in younger relapsed b-all
Published 4 years ago • 1.5K plays • Length 4:36Download video MP4
Download video MP3
Similar videos
-
2:44
promising results for blinatumomab in younger b-all at first relapsed
-
2:28
blinatumomab as consolidation for adult b-all
-
1:54
final results of the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph- b-all
-
1:22
final results of allg all08: blinatumomab with reduced intensity chemo in older adults with b-all
-
3:04
b-all patient selection for treatment with blinatumomab
-
2:26
optimizing blinatumomab for b-all
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
9:44
an update on the quantum-first trial: quizartinib plus chemotherapy in flt3-mutated aml
-
3:19
blinatumomab plus ponatinib for ph all
-
1:35
outcomes of allosct following blinatumomab in children and young adults with r/r b-all
-
2:47
blinatumomab therapy following hyper-cvad in b-cell all
-
1:03
updated results of hyper-cvad and blinatumomab /- inotuzumab ozogamicin in newly-diagnosed b-all
-
2:24
novel all treatment strategies: blinatumomab
-
1:39
an update on the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph-like all
-
2:32
blinatumomab and ponatinib in newly diagnosed ph all: updates from a phase ii trial
-
1:35
neuf: real-world data on blinatumomab for all
-
1:05
comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed ph b-all
-
2:23
the value of blinatumomab in all and future therapeutic considerations
-
4:24
updates on bites for b-all
-
3:04
immunotherapy for frontline treatment of all: inotuzumab ozogamicin and blinatumomab
-
1:37
genomic determinants of response to blinatumomab